Using blood conservation technique during heart surgery to assess kidney function
Effect of Low-volume Fluid Replacement Strategy During Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels: an Acute Kidney Injury Biomarker
This study is testing if a blood-saving technique during heart surgery can help improve kidney function in patients while also reducing the need for blood transfusions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University of Maryland, Baltimore Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT05349292 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effects of acute normovolemic hemodilution (ANH) on urine neutrophil gelatinase-associated lipocalin levels in patients undergoing elective coronary artery bypass graft (CABG) surgery. A total of 50 adult patients under 70 years old will be randomly assigned to receive either ANH or standard care without ANH during their surgery. The study aims to determine if ANH can improve kidney function indicators while reducing the need for blood transfusions. Exclusion criteria include patients with renal insufficiency, significant comorbidities, or those undergoing emergency surgeries.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 undergoing elective CABG surgery with a predicted cardiopulmonary bypass duration of less than 2 hours.
Not a fit: Patients with renal insufficiency, significant heart or lung diseases, or those requiring emergency surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved kidney function outcomes and reduced blood transfusion needs for patients undergoing heart surgery.
How similar studies have performed: Previous studies have shown improvements in blood transfusion rates with similar techniques, but this specific approach is being evaluated for the first time regarding kidney function.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Elective Coronary Artery Bypass Graft Surgery * Age 18-70 years * Anticipated Cardiopulmonary Bypass Duration less than 2 hours * Weight greater than 70kg * Hemoglobin greater than 12 g/dL Exclusion Criteria: * Emergency and redo cardiac surgery * Renal insufficiency with serum creatinine greater than 1.25 mg/dL and/ or estimated GFR less than 60 mL/min/1.73 m2 * Heart Failure with EF \<40% * Hepatic disease * Pulmonary Disease, including pulmonary hypertension * Inherited or Acquired Bleeding Disease
Where this trial is running
Baltimore, Maryland
- University of Maryland Medical Center — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Patrick Odonkor, MD — University of Maryland, Baltimore
- Study coordinator: Patrick Odonkor, MD
- Email: podonkor@som.umaryland.edu
- Phone: 4103286120
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.